| |
UAE
|
eGFR
|
|---|
|
β (95% CI)
|
p values
|
β (95% CI)
|
p values
|
|---|
|
CIMT
|
|
Model 1
|
0.10 (0.06–0.14)
|
< 0.001
| − 0.23 (-0.27∽-0.20) |
< 0.001
|
|
Model 2
|
0.07 (0.04–0.11)
|
< 0.001
|
− 0.02 (-0.06–0.03)
|
0.461
|
|
Model 3
|
0.07 (0.03–0.10)
|
< 0.001
|
− 0.01 (-0.05–0.03)
|
0.486
|
|
Model 4
|
0.05 (0.02–0.09)
|
0.006
|
− 0.01 (-0.05–0.03)
|
0.660
|
|
Model 5
|
0.05 (0.01–0.09)
|
0.029
|
− 0.01 (-0.05–0.04)
|
0.701
|
|
FIMT
|
|
Model 1
|
0.10 (0.06–0.14)
|
< 0.001
| − 0.27 (-0.31∽-0.23) |
< 0.001
|
|
Model 2
|
0.08 (0.04–0.11)
|
< 0.001
|
− 0.04 (-0.08–0.00)
|
0.053
|
|
Model 3
|
0.07 (0.04–0.11)
|
< 0.001
|
− 0.04 (-0.08–0.00)
|
0.052
|
|
Model 4
|
0.08 (0.04–0.12)
|
< 0.001
|
− 0.04 (-0.08–0.00)
|
0.070
|
|
Model 5
|
0.07 (0.03–0.11)
|
0.001
|
− 0.04 (-0.08–0.01)
|
0.134
|
- UAE urinary albumin excretion, eGFR estimated glomerular filtration rate, DD duration of diabetes, APA anti-platelet agents, LLD lipid-lowering drugs, AHA anti-hypertensive agents, SBP systolic blood pressure, DBP diastolic blood pressure, WC waist circumference, WHR waist-to-hip ratio, BMI body mass index, FPG fasting plasma glucose, 2-h PPG 2-h postprandial plasma glucose, HbA1c glycated hemoglobin A1c, FCP fasting C-peptide, 2-h PCP 2-h postprandial C-peptide, HOMA2-IR HOMA of insulin resistance, TG total triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ALT alanine transaminase, SUA serum uric acid
- Model 1: unadjusted
- Model 2: Adjusted for age, sex, DD, hypertension, smoking status and alcohol use
- Model 3: Further adjustment for use of AHA, LLD, APA
- Model 4: Further adjustment for SBP, DBP, BMI, WC and WHR
- Model 5: Further adjustment for ALT, TG, TC, HDL-C, LDL-C, SUA, FPG, 2-h PPG, HbA1c, FCP, 2-h PCP, HOMA2-IR
